STEFAN VAN DER MEULEN

Based outside Ghent, Belgium, Stefaan Van der Meulen heads the Global Clinical Business Development team for NAMSA. Prior to this he was leading the Syntactx offices in Europe as a Managing Partner also overseeing business development for the company on a global scale.

Stefaan began his career in the pharmaceutical industry working on early- and late-phase clinical research studies of various sizes and indications. While working at Novartis, he was a global co-driver for their risk-based monitoring initiative, a best practice that is now being applied at Syntactx. At Cordis, a medical device developer and manufacturer, Stefaan concentrated on first-in-human and pivotal studies before transitioning to Core Laboratory and product specialist activities. He also has experience in product life-cycle development from both a clinical and marketing perspective.
Stefaan holds a Master of Biomedical Sciences from Ghent University in Belgium. He is fluent in Dutch, English, and French, and proficient in Italian and German.